Kornimate/medical-research-clean huggingface dataset:
early intelligent diagnosis of limb deformity in children by ai and clinic application

Conditions: Limb Deformity

Summary: the limb deformity in children include congenital limb malformations or acquired from the damage of epiphyseal plate which caused by tumor, inflammation and trauma. due to the complexity of the disease itself, rapid dynamic development and the characteristics of children's growth and development, the deformities are constantly changing. in addition, the serious lack of clinical diagnosis and treatment resources in the department of pediatric orthopedics has led to the misdiagnosis and improper treatment of children's limb deformities. thus, its necessary to find an intelligent way to help doctor to early diagnosis of limb deformity and provide a proper treatment in children.

the extraction and application of big data of children's limb deformities, intelligent labeling of image data, precise positioning, and perfecting the anatomical data of children's limb deformities.improve the positioning accuracy of key points in x-ray images of children's limb deformities by means of step-by-step supervision to improve the accuracy of diagnosis.realize an intelligent report generation system that combines patient background information, establish an end-to-end auxiliary diagnosis and treatment suggestion demonstration application system; realize a full set of artificial intelligence solutions for children's skeletal deformities, early screening and diagnosis of children, and forming an intelligent referral system of children's limb deformities.

Eligibility criteria:
inclusion criteria: children with limb deformity exclusion criteria: children without limb deformity

Keywords: limb deformity; pediatrics ; artificial intelligence
outcome of transforminal epidural injections in patients with lumbar radicular pain

Conditions: Lumbar Redicular Pain

Summary: back pain is the most common chronic pain disorder of adult population. lumbar radicular pain occurs due to irritation or compression of the nerve roots in the lower back. various non-surgical methods can also be exercised that have been used to treat lumbar radicular pain since the ancient times. despite the availability of various treatment options, achieving optimal pain relief and functional recovery remains challenging. lumbar transforaminal epidural steroid injections (tfesi) are commonly used to manage this condition, but there is variability in patient response and limited data on the effectiveness of tfesi in different demographic and clinical subgroups.


Eligibility criteria:
inclusion criteria: * both genders * aged between 45 and 80 years * experiencing lumbar radicular pain exclusion criteria: * history of spinal fracture or previous spinal surgery * recurrent pain within 3 months of prior treatment * ongoing steroid therapy * iknown allergy to dexamethasone or lidocaine
chest mobility exercises versus proprioceptive neuromuscular facilitation in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease Moderate

Summary: chest mobility exercise versus proprioceptive neuromuscular facilitation in patients with chronic obstructive pulmonary disease

the purpose of this study is designed to compare the therapeutic effect of chest mobility exercises and proprioceptive neuromuscular facilitation stretching on improving chest expansion and functional capacity in patients with chronicobstructivepulmonarydisease?

Eligibility criteria:
inclusion criteria: all patients will have the following criteria: 1. age: 50-60 years old 2. all patients will be in mild to moderate of copd. in accordance with criteria of global initiative for chronic obstructive lung disease (gold) (gold i-ii). 3. bmi: obese class 1 (30-34.9). 4. sex: male 5. they suffered from mild dyspnea, chronic cough and expectorations, with forced expiratory volume in one second (fev1sec) from 50% to 80% of predicted value. exclusion criteria: patients with the following criteria will excluded from the study: 1. severe psychiatric or cognitive impairments. 2. progressive neuromuscular disorders. 3. decreased level of consciousness. 4. unstable fracture. 5. pacemaker inserted for fewer than 2 days 6. deep-venous thrombosis (to minimize risk for pulmonary embolism from being in a prone position. 7. mean arterial blood pressure of less than 65 mm hg with or without vasopressors. 8. tracheal surgery or sternotomy in the last 15 days. 9. massive haemoptysis. 10. intracranial pressure of more than 30 mm hg or cerebral perfusion pressure of less than 60 mm hg.
comparison of vitamin d status and vitamin d receptor polymorphisms in patients with high myopia and primary open-angle glaucoma

Conditions: Vitamin D Deficiency; Primary Open-angle Glaucoma; High Myopia; Vitamin D Receptor Polymorphisms

Summary: vitamin d deficiency is known to be significantly associated with high myopia. this study investigated the vitamin d status in patients with high myopia and primary open-angle glaucoma, in order to understand the relationship between high myopia and the development of primary open-angle glaucoma.110 primary open-angle glaucoma patients, 110 high myopia patients and 110 age-matched people in the han population were enrolled. serum levels of 1a, 25-dihydroxyvitamin d3 were measured by an enzyme-linked immuno-absorbent assay.vitamin d receptor polymorphic analysis was studied by polymerase chain reaction-restriction fragment length polymorphism technique.


Eligibility criteria:
inclusion criteria: -primary open-angle glaucoma (1) intraocular pressure above 21 mmhg or more in each eye without therapy; (2) wide anterior chamber angle; (3)glaucomatous optic neuropathy (glaucomatous optic nerve damage was defined as cup-to-disc ratio higher than 0.7 or focal loss of the nerve fiber layer (notch) associated with a consistent glaucomatous visual field defect in at least one eye;(4) visual field loss consistent with optic nerve damage and visual fields were performed by using standard automated perimetry in at least one eye. c(with refractive error \>6d) were recruited. exclusion criteria: * the presence of any secondary glaucoma with an exfoliation syndrome or a history of ocular trauma, high myopia, macular degeneration, other ocular diseases, and also a known history of systemic diseases and administration of vitamin d3 or other analog. high myopia patients with ocular disease such as glaucoma, a history of administration of vitamin d3 or other analog or a history of retinopathy or connective tissue disorders associated with myopia, such as stickler or marfan syndromes, were not included.
immediate postoperative bevacizumab administration in proliferative diabetic retinopathy patients undergoing vitrectomy

Conditions: Proliferative Diabetic Retinopathy - High Risk

Summary: patients undergoing surgery for complications related to diabetes will be recruited.

proliferative diabetic retinopathy patients undergoing pars plana vitrectomy will be randomized whether or not to receive intravitreal bevacizumab at the conclusion of the operation.

Eligibility criteria:
inclusion criteria: 1. subject age is \> 18 2. subject consents to study participation and is capable of 6 months of follow-up. 3. the subject has type i or ii diabetes mellitus with active pdr in the study eye. 4. best-corrected spectacle visual acuity (bcsva) on the snellen eye chart ranges from 20/40 to hand motions in the study eye. 5. the subject is determined to need a ppv because of reduced bcsva principally from a non-clearing vitreous hemorrhage, trd, fibrous proliferation, or a combination of the three. when non-clearing vitreous hemorrhage is the principal reason for ppv, the hemorrhage must have been present by subjective history for at least 3 months. when trd is the principal reason for ppv, the trd must be threatening (within one disc diameter) or involving the fovea. when fibrovascular proliferation is the principal reason for ppv, it must be extensive (\>3 clock hours) and threatening (within one disc diameter) or involving the fovea. 6. only one eye per patient is eligible for the study. exclusion criteria: 1. subject is known to have a significant retinal/optic nerve disease otherwise unrelated to diabetes mellitus, which in the opinion of the examiner is responsible for two or more lines of reduced bcsva (macular degeneration, optic neuritis, glaucoma, amblyopia, etc.) in the study eye. 2. subject has a significant corneal opacity, which in the opinion of the examiner, is responsible for two or more lines of reduced bcsva (corneal scar, ectasia, etc.) in the study eye. 3. subject has had a previous vitrectomy (anterior or ppv) in the study eye. 4. subject has uncontrolled neovascular glaucoma (intraocular pressure \> 30 mmhg despite medical/surgical treatment) in the study eye. 5. subject has uncontrolled hypertension (systolic \> 200 mmhg or diastolic \> 120 mmhg) despite adherence to a multiple anti-hypertensive medication regimen. -

Keywords: proliferative diabetic retinopathy bevacizumab vitreous hemorrhage
transcranial magnetic stimulation in children with stroke

Conditions: Hemiparesis; Neonatal Stroke; Ischemic Stroke; Hemorrhagic Stroke; Thrombotic Stroke

Summary: this is a pilot study of repetitive transcranial magnetic stimulation (rtms) to test tolerance and efficacy in children who have hemiparesis from acquired or presumed perinatal stroke.

the investigators will begin to test the hypothesis that rtms will be tolerated and will result in improved hand strength and mobility when compared with sham stimulation. aim 1: to determine whether 1 hz rtms applied to the hemisphere opposite the infarct (contralesional or healthy hemisphere) is tolerated by children ages 6-18 years who have chronic motor sequelae from a stroke. aim 2: to determine whether 8 sessions of inhibitory 1 hz rtms to the contralesional healthy hemisphere improves grip strength and hand mobility when compared with sham stimulation in controls.

Eligibility criteria:
inclusion criteria: 1. a history of ischemic or hemorrhagic stroke at least 6 months prior to recruitment, and causing current unilateral motor impairment of hand function (scoring 1-3 on a modified ashworth scale; scale explained in appendix). 2. cerebral infarction spares the transcallosal pathways. 3. cerebral injury confirmed by brain mri or ct 4. ages 6-18 years inclusive. exclusion criteria: 1. the presence of an implanted device such as a pacemaker, vagal nerve stimulator, or recently implanted cardiovascular stent; arterial aneurysms; arteriovenous malformations; obstructive hydrocephalus. 2. infarction of the cortical motor areas. 3. presence of a brain tumor or suspected neurodegenerative disease. 4. intractable epilepsy or a history of poorly controlled epilepsy. 5. current use of medications that may lower seizure threshold (such as specific antipsychotics, specific antidepressants, amphetamines) 6. hand function limited to rigid flexion or extension (score = 4 on the modified ashworth scale) 7. disorders causing hallucinations, delusions, or excessive anxiety or depression. 8. pre-existing chronic pain syndromes including intractable headache and chronic daily headache. 9. pregnancy. 10. any sensorimotor or cognitive impairment that prevents valid responses on study measures. 11. bilateral strokes (cerebral injuries) involving motor cortex and/or corpus callosum 12. all patients and parents must be naïve regarding the effects and sensations of rtms (i.e., patients and/or parents with prior exposure to tms will be excluded). 13. subject has had a recent neurosurgical procedure involving the brain. 14. subject suffered traumatic brain injury that places the subject at risk of seizures.

Keywords: childhood stroke perinatal stroke pediatric stroke presumed perinatal stroke children who have hemiparesis
radiofrequency ablation in relieving pain in patients with bones metastases

Conditions: Metastatic Cancer; Pain

Summary: rationale: radiofrequency ablation uses high-frequency electric current to kill tumor cells and may help to relieve pain caused by bone metastases. purpose: phase ii trial to study the effectiveness of radiofrequency ablation in relieving pain in patients who have bone metastases.

objectives: * determine the efficacy of radiofrequency ablation, in terms of pain relief at 4 weeks, in patients with painful bone metastases. * determine the safety of this regimen in these patients. * compare the change in pain interference with daily life and analgesic use at 4 weeks vs baseline in patients treated with this regimen. * determine the time to recurrence of worst pain in patients treated with this regimen. outline: this is a multicenter study. patients receive radiofrequency ablation (rfa) to targeted tumor(s) on day 0 (multiple tumors may receive ablation in multiple sessions). patients who achieve a reduction in worst pain of at least 2 points within 4-8 weeks but experience recurring pain at the rfa site or are diagnosed with a new painful lesion within 4-24 weeks receive 1 additional treatment to the recurring or new site. pain (using the brief pain inventory scale of 0-10), analgesic use, and quality of life are assessed at baseline, on day 1, weekly for 4 weeks, and then every 2 weeks for 20 weeks. patients are followed for 6 months beyond the last rfa treatment. projected accrual: a maximum of 50 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed bone metastases * pain refractory to non-opioid analgesic medication and radiotherapy or * patient is considered a poor candidate for opioid analgesics or radiotherapy * initial worst pain score within the past 24 hours at least 4 on a scale of 0-10 * tumors deemed accessible for radiofrequency ablation * no evidence of impending fracture in weight-bearing bones (more than 50% loss of cortical bone) * tumors must be more than 1 cm from critical structures including: * spinal cord, brain, or other critical nerve structures * large abdominal vessel (e.g., aorta or inferior vena cava) * bowel or bladder patient characteristics: age: * 18 and over performance status: * not specified life expectancy: * more than 2 months hematopoietic: * platelet count at least 75,000/mm3 hepatic: * inr less than 1.5 renal: * not specified other: * not pregnant or nursing * negative pregnancy test prior concurrent therapy: biologic therapy: * not specified chemotherapy: * at least 3 weeks since prior chemotherapy endocrine therapy: * not specified radiotherapy: * at least 3 weeks since prior radiotherapy surgery: * not specified other: * at least 3 days since prior aspirin, ibuprofen, or other nonsteroidal anti-inflammatory drugs * no concurrent anticoagulants

Keywords: bone metastases pain
the geneva covid-19 cvd study

Conditions: COVID; CVD

Summary: in this study, the investigators propose to analyse the clinical data of all patients admitted in geneva university hospitals (hug) or in a care center in geneva who are diagnosed with covid-19. cvd being one of the most important risk factors for developing a severe form of the disease, the investigators will explore the prognosis and clinical outcomes of those patients according to their cvd history as well as newly onset cvd during hospitalization. moreover, as further evidence is needed on the use of renin-angiotensin-aldosterone system (raas) inhibitors for sars-cov-2 infected patients, the investigators will study prognosis and outcomes according to the patients' medications. finally, the investigators propose to evaluate hospital length of stay and cost. the aim, therefore, is to collect information and scientific evidence from patients hospitalized and diagnosed positive for covid-19, in order to evaluate if previous (or newly onset) cvd may influence outcomes and costs.

hypothesis: covid-19+ hospitalized patients with preexisting cvd or newly onset cvd at time of hospitalization have different clinical outcomes compared to those without cvd and covid-19+. objectives: the primary aim of this study is to gather observational data, starting from february 1st 2020 until the end of the pandemic, to compare clinical outcomes covid+ hospitalized patients at hug or in a care center in geneva with pre-existing or newly onset cvd, to covid+ hospitalized patients at hug or in a care center in geneva without pre-existing cvd. the secondary aims of this study are: * to determine the association between covid-19 disease and cvd, based on: age, previous cv diseases, cv risks factors, cv medications (e.g. ace inhibitors or angiotensin ii receptor antagonists) * to explore cvd profiles that may influence covid-19 disease outcomes * to determine the cause of death in cvd patients (either with preexisting cvd or newly diagnosed with cvd) * to understand the vulnerability of the myocardium (new event of either heart failure, acute coronary syndrome, arrhythmia, myocarditis) in patients with covid-19 disease.

Eligibility criteria:
inclusion criteria: * subject is ≥18 years of age. * patient diagnosed sars-cov-2 positive at time of hospitalization. * in case of the subject accepting the follow-up at 30 days and 1 year, signed patient informed consent (pic) form exclusion criteria: * patients unwilling to provide informed consent for the follow-up.
safety/effectiveness study of a single session of laying-on-of-hands in various settings in japan

Conditions: Signs and Symptoms; Physical Disorders; Personal Satisfaction

Summary: the purpose of this study is to determine the symptomatic changes after a single session of laying-on-of-hands in various settings, and to evaluate optimal conditions for the outcomes.

laying-on-of-hands is applied in many different situations; however, most reports published previously described its efficacy in a clinical setting, with its administration conducted by a few expert practitioners. this study aimed to determine the symptomatic changes after a single session of the okada purifying therapy, a form of laying-on-of-hands, in various settings, and to analyze factors influencing the outcomes.

Eligibility criteria:
inclusion criteria: * able to receive laying-on-of-hands for 30 minutes or longer from the investigators * able to self-evaluate the change of their symptoms * competent to answer the japanese questionnaires * aged 16 years or older exclusion criteria: * those who did not match the inclusion criteria

Keywords: laying-on-of-hands therapeutic touch cross-sectional study healing environment safety and effectiveness optimal condition for the intervention
effect of pomegranate seed powder on markers of metabolic syndrome

Conditions: Metabolic Syndrome

Summary: metabolic syndrome is a public health concern worldwide and in pakistan as well. abdominal obesity, hyperglycemia, hypertriglyceridemia, hypertension, and low hdl cholesterol are its hallmarks while pomegranate seed's unique chemical composition has sparked research into the health benefits in same arena as weight control, blood lipid profile changes, and other metabolic disturbances. it's high time to study therapeutic efficiency of pomegranate seed powder against metabolic syndrome.

metabolic syndrome, accumulation of certain metabolic risk factors, such as abdominal obesity, hyperglycemia, hypertriglyceridemia, hypertension, and low hdl cholesterol, has been noted as one of the most important risk factors for the epidemic of type 2 diabetes and cardiovascular disease in the 21st century. it has become a significant public health concern and a global epidemic with a prevalence rate of about 25% among american adults. multiple researches have demonstrated the effectiveness of pomegranate in the management of diabetes, inflammatory conditions, obesity, and blood lipid levels, and consequently metabolic syndrome. various pomegranate components have the potential to substitute anti-diabetic medications as well pomegranate seed's unique chemical composition has sparked research into the health benefits, such as weight control, blood lipid profile changes, and other metabolic disorders. seed powder can influence the patient's metabolic syndrome-related indicators. hypothesis: pomegranate seed powder can be effective to treat the individuals with impaired metabolism. methodology: in a clinical trial, patients of metabolic syndrome (n=50) will be given pomegranate seed powder dose for over 8 weeks, twice a day. biochemical outcomes including blood pressure, fbg, cholesterol, hemoglobin level will be determined before and after the completion of trial in addition to patient's weight. finally, using one-way anova and t-test, collected data will be analyzed. expected outcome: the study will explore the potential of pomegranate seed powder in treating metabolic syndrome's risk factors. therefore, our findings on the studied parameters of patient will assist future researchers in developing tested, evidence-based recommendations.

Eligibility criteria:
inclusion criteria: * bmi \> 25kg/m2 * dyslipidemia * altered blood glucose level * age 30-55 ( male and female) exclusion criteria: * thyroid disorder * liver disease * kidney disorder * cancer etc

Keywords: metabolic syndrome hypertension obesity insulin resistance diabetes pomegranate seed powder dyslipidemia
study of pga suture in ophthalmology

Conditions: Glaucoma

Summary: to evaluate the safety and efficacy of polyglycolic acid suture in ophthalmic surgical procedures

the sutures are classified into non-absorbable and absorbable sutures. violet braided polyglycolic acid suture is the synthetic absorbable suture used in wound closure in ophthalmology, cardiology, neurology and plastic \& reconstructive surgeries. in ophthalmology, pga sutures are used in trabeculectomy (glaucoma), orbit and oculoplasty, lid and socket reconstruction, squint, ptosis and retinal detachment surgeries. glaucoma patients who met the inclusion criteria were recruited for this study. uniform surgery and suturing technique was performed in all patients (trabeculectomy with iol implantation). surgeon assessed suture characteristics during surgery and wound integrity at the end of surgery. patients were followed up during 1 day, 1 month and 3 months post operatively. visual acuity, intraocular pressure (iop), suture characteristics, wound integrity, inflammation and conjunctival status were examined during each follow up visit.

Eligibility criteria:
inclusion criteria: * patients undergoing trabeculectomy with iol implantation * current residence within 60 kms of madurai exclusion criteria: * life threatening illness * immunosuppressive disorders * chronic infection

Keywords: glaucoma trabeculectomy sutures